Toward point-of-care testing for @entity4016 XXXX mutation on a microchip.

@entity1 @entity6582 @entity5 @entity4016 @entity1583 @entity4017
UNASSIGNED: Molecular genetics now plays a crucial role in diagnosis, the identification of prognostic markers, and monitoring of @entity1583 . Demonstration of acquired changes such as the @entity4016 @entity4017 mutation within @entity5 ( @entity5 ) has quickly moved from a research setting to the diagnostic laboratory. Microfluidics-based assays can reduce the assay time and sample/reagent consumption and enhance the reaction efficiency; however, no current assay has integrated isothermal amplification for point-of-care @entity5 @entity4016 @entity4017 mutation testing with a microchip. In this report, an integrated microchip that performs the whole @entity1 blood genomic DNA extraction, loop-mediated isothermal nucleic acid amplification (LAMP) and visual detection for point-of-care genetic mutation testing is demonstrated. This method was validated on DNA from cell lines as well as on whole blood from @entity1 with @entity5 . The results were compared with those obtained by unlabeled probe melting curve analysis. This chip enjoys a high accuracy, operability, and cost/time efficiency within 1h. All these benefits provide the chip with a potency toward a point-of-care genetic analysis. All samples identified as positive by unlabeled probe melting curve analysis (n=27) proved positive when tested by microchip assay. None of the 30 negative controls gave false positive results. In addition, a @entity1 with @entity6582 vera diagnosed as being @entity4016 @entity4017 -negative by unlabeled probe melting curve analysis was found to be positive by the microchip. This microchip would possibly be very attractive in developing a point-of-care platform for quick preliminary diagnosis of @entity5 or other severe illness in resource-limited settings.
